6. Cardiometabolic and Musculoskeletal Health at Menopause
Pedagogy: This lesson uses risk-integration reasoning — teaching clinicians to see menopause as a cardiometabolic turning point and the menopause consultation as a cardiovascular risk assessment opportunity.
Learning Objectives
- Describe the accelerated atherosclerosis associated with the menopausal transition
- Explain the cardiometabolic changes by menopausal stage using the Ravindran-Varma framework
- Recognise VMS as a biomarker of cardiovascular risk
- Apply QRISK3 and the five-step precision menopause pathway at the menopause consultation
Key Facts
Menopause as a Cardiometabolic Turning Point
CVD is the leading cause of death in postmenopausal women. The menopausal transition is associated with accelerated atherosclerosis driven by oestrogen withdrawal, adverse lipid changes, increasing insulin resistance, and visceral fat accumulation (1,2).
Cardiometabolic Changes by Menopausal Stage
| Stage | Key Metabolic Features | MetS Prevalence |
|---|---|---|
| Premenopause | Favourable oestrogen/androgen ratio; gynecoid fat; insulin-sensitive | 7-20% |
| Perimenopause | Declining oestrogen; visceral adiposity rising; LDL/TG/BP increasing; insulin resistance onset | Rises sharply around FMP |
| Postmenopause | Low oestrogen, high FSH; marked visceral fat; dyslipidaemia; impaired glucose tolerance; hypertension | 32-58% |
Adapted from Ravindran and Varma (2026) (1).
VMS as a Cardiovascular Biomarker
Meta-analysis of 213,000+ women: VMS associated with CHD (RR 1.34), stroke (RR 1.30), and composite CVD (RR 1.48). VMS may signal underlying endothelial dysfunction and sympathetic activation (1).
The Five-Step Precision Menopause Pathway
1. Symptom relief: Transdermal oestradiol + matched progestogen. 2. CVD risk assessment: QRISK3, BP, fasting lipids, HbA1c, BMI, waist circumference. 3. Lifestyle modification: Exercise 150 min/week + resistance training, weight management, smoking cessation, alcohol limit. 4. Pharmacological prevention: Statins if QRISK3 >=10%; antihypertensives as indicated. 5. Ongoing monitoring: 3-month HRT review, then annual (1).
Clinical Pearl HRT is for symptom relief. The menopause consultation is your opportunity for CVD risk assessment. Do both — simultaneously. This is precision menopause management.
Clinical Pearl Metabolic syndrome prevalence rises from 7-20% premenopause to 32-58% postmenopause. QRISK3 should be calculated at every menopause consultation.
Case-Based Examples
Case 1: 52-year-old with VMS and undiagnosed metabolic risk
Presentation: A 52-year-old presents with VMS. On assessment: BP 148/92, BMI 32, waist 96cm, fasting glucose 6.4 mmol/L. She has not had bloods checked in 5 years. Family history of MI (father aged 58).
Question: How would you apply the precision menopause pathway?
Model Answer: Step 1: Symptom relief — transdermal oestradiol (preferred given BMI >30) + micronised progesterone. Step 2: CVD risk — calculate QRISK3 (likely elevated given BP, BMI, family history, impaired fasting glucose). Order fasting lipids and HbA1c. Step 3: Lifestyle — dietary counselling (Mediterranean diet), exercise prescription (150 min/week + resistance), weight target (5-10% loss). Step 4: Pharmacological — if QRISK3 >=10%: discuss statin. Antihypertensive for BP 148/92 (treat to target). Repeat fasting glucose — may need HbA1c to assess for prediabetes/T2DM. Step 5: Review at 3 months (HRT + BP + lifestyle progress), then annually.
Case 2: 48-year-old with severe VMS asking 'Will HRT protect my heart?'
Presentation: A 48-year-old with severe VMS, BMI 24, no CVD risk factors asks whether HRT will protect her cardiovascular system.
Question: How do you counsel her?
Model Answer: Acknowledge her question directly. Explain: the hormonal changes at menopause do increase CVD risk over time, and her severe VMS may signal underlying vascular changes (meta-analysis: RR 1.48 for composite CVD). However, NICE NG23 (2024) is clear: do not prescribe HRT for CVD prevention. The evidence from RCTs does not support this indication. She should take HRT for symptom relief — which is entirely appropriate. Simultaneously: calculate QRISK3 (even though she is low-risk, establishing a baseline is valuable), check BP, fasting lipids, HbA1c. Recommend: transdermal HRT (standard start), exercise, Mediterranean diet. Frame it positively: the menopause consultation is the perfect time to invest in long-term cardiovascular health alongside treating symptoms.
Self-Assessment Questions
PLAB/MLA VMS and cardiovascular risk
What is the association between VMS and composite CVD risk?
A. No association
B. RR approximately 1.48 in meta-analysis
C. VMS reduce CVD risk
D. Association only in smokers
Answer: B. Meta-analysis of 213,000+ women: VMS associated with composite CVD RR 1.48.
MRCGP Precision menopause management in practice
A 50-year-old with VMS and BMI 34 attends for HRT. Her QRISK3 is 12%. How do you incorporate CVD prevention?
A. HRT alone will reduce her CVD risk
B. Prescribe transdermal HRT for symptoms; simultaneously start statin (QRISK3 >=10%), address BP, and prescribe lifestyle modification
C. Defer HRT until CVD risk is controlled
D. Refer to cardiology before starting HRT
Answer: B. Precision menopause management: treat symptoms (transdermal HRT) AND address CVD risk (statin, antihypertensives, lifestyle) simultaneously. Do not withhold HRT while managing CVD risk.
Professor NICE vs 'window of opportunity' for CVD
Critically evaluate why NICE NG23 does not endorse the 'window of opportunity' hypothesis for cardiovascular benefit of HRT.
A. NICE ignores all evidence
B. NICE applies strict RCT-evidence hierarchy; WHI subgroup analyses showing reduced CVD in younger women were not statistically significant across subgroups; observational data (DOPS) are supportive but not definitive
C. The window of opportunity has been disproven
D. NICE supports the hypothesis but cannot mandate it
Answer: B. NICE found no statistically significant interaction between age/time-since-menopause and CVD outcomes in WHI subgroup analyses. The apparent benefit in the 50-59 subgroup lost significance when tested against other age groups. DOPS was open-label and small. NICE's position is methodologically rigorous but pragmatically conservative — the ESE and BMS acknowledge the observational signal while agreeing HRT should not be prescribed specifically for CVD prevention.
Take-Away Messages
- Menopause is a cardiometabolic turning point — metabolic syndrome prevalence rises from 7-20% to 32-58%
- VMS are independently associated with increased CVD risk (RR 1.48 for composite CVD)
- HRT is for symptom relief, NOT for CVD prevention (NICE NG23, 2024)
- Use the menopause consultation for QRISK3, fasting lipids, HbA1c, BP, waist circumference
- The five-step precision pathway: symptom relief + CVD assessment + lifestyle + pharmacological prevention + monitoring